|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 324.40 SEK | +0.37% |
|
+2.14% | +4.38% |
| 08/05 | US FDA Extends Review Period for BioArctic's Co-developed Alzheimer's Therapy | MT |
| 08/05 | Futures point to negative opening for Stockholm Stock Exchange (update) | FW |
Company Valuation: BioArctic AB
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 10,497 | 23,972 | 23,651 | 17,634 | 27,550 | 28,781 | - | - |
| Change | - | 128.37% | -1.34% | -25.44% | 56.23% | 4.47% | - | - |
| Enterprise Value (EV) 1 | 9,664 | 23,176 | 23,044 | 17,175 | 26,553 | 28,254 | 27,268 | 27,426 |
| Change | - | 139.82% | -0.57% | -25.47% | 54.61% | 6.4% | -3.49% | 0.58% |
| P/E ratio | -87.6x | -2,092x | 103x | -99.8x | 27x | 492x | 32.3x | 83.6x |
| PBR | 13.3x | 30.5x | 22.6x | 19.7x | 14x | 13.1x | 10.1x | 11.9x |
| PEG | - | 23.1x | -0x | 1x | -0x | -5.2x | 0x | -1.4x |
| Capitalization / Revenue | 454x | 104x | 38.4x | 68.5x | 13.8x | 23x | 15.9x | 13.1x |
| EV / Revenue | 418x | 101x | 37.4x | 66.7x | 13.3x | 22.6x | 15.1x | 12.5x |
| EV / EBITDA | -76.3x | -8,251x | 85x | - | - | 41.2x | 29.3x | 16.5x |
| EV / EBIT | -69.2x | -1,329x | 91.2x | -75.2x | 21.1x | 106x | 31x | 26.7x |
| EV / FCF | -66.7x | -522x | 76.2x | -50.1x | - | -67.9x | 31.2x | 86.1x |
| FCF Yield | -1.5% | -0.19% | 1.31% | -2% | - | -1.47% | 3.21% | 1.16% |
| Dividend per Share 2 | - | - | - | - | 2 | 2 | 1 | 2 |
| Rate of return | - | - | - | - | 0.64% | 0.62% | 0.31% | 0.62% |
| EPS 2 | -1.36 | -0.13 | 2.59 | -2 | 11.52 | 0.66 | 10.04 | 3.88 |
| Distribution rate | - | - | - | - | 17.4% | 303% | 9.96% | 51.5% |
| Net sales 1 | 23.15 | 229.9 | 616 | 257.4 | 1,999 | 1,252 | 1,806 | 2,191 |
| EBITDA 1 | -126.6 | -2.809 | 271.1 | - | - | 686 | 930 | 1,662 |
| EBIT 1 | -139.7 | -17.44 | 252.6 | -228.5 | 1,259 | 265.7 | 879 | 1,027 |
| Net income 1 | -119.8 | -11.18 | 229.2 | -177.1 | 1,022 | 258 | 847 | 342 |
| Net Debt 1 | -832.5 | -795.3 | -606.6 | -458.7 | -996.4 | -526.5 | -1,513 | -1,354 |
| Reference price 2 | 119.20 | 272.00 | 267.80 | 199.50 | 310.80 | 324.40 | 324.40 | 324.40 |
| Nbr of stocks (in thousands) | 88,060 | 88,132 | 88,315 | 88,389 | 88,641 | 88,719 | - | - |
| Announcement Date | 03/02/22 | 03/02/23 | 14/02/24 | 13/02/25 | 18/02/26 | - | - | - |
1SEK in Million2SEK
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 491.52x | 22.56x | 41.19x | 0.62% | 304.9Cr | |
| 28.4x | 5.05x | 15.65x | 1.16% | 4.17TCr | |
| 44.43x | 4.44x | 28.31x | -.--% | 3.26TCr | |
| -18.41x | 283.77x | -16.54x | -.--% | 3.1TCr | |
| 20.59x | 2.44x | 10.54x | -.--% | 2.82TCr | |
| 30.22x | 7.79x | 20x | 0.41% | 2.64TCr | |
| -20.76x | 13.53x | -20.96x | -.--% | 1.23TCr | |
| 20.54x | 1.83x | 8.04x | 1.3% | 1.21TCr | |
| Average | 74.56x | 42.68x | 10.78x | 0.44% | 2.34TCr | |
| Weighted average by Cap. | 26.34x | 51.65x | 9.90x | 0.41% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- BIOA B Stock
- Valuation BioArctic AB
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition